Setara gets $90M to continue rare disease pipeline spun out of Jazz's Actio deal
After shipping its precision epilepsy drug to Jazz Pharmaceuticals, Actio Biosciences has spun out the remainder of its genetics-driven pipeline into a new company called Setara Biosciences. Setara is getting a fresh $90 million to ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.